Microcirculatory alteration in low-grade gastric mucosa-associated lymphoma by Helicobacter heilmannii infection: its relation to vascular endothelial growth factor and cyclooxygenase-2.
BACKGROUND
There are clinical reports that Helicobacter heilmannii, as well as Helicobacter pylori, has been clinically reported to cause gastric low-grade mucosa-associated lymphoid tissue-type (MALT) lymphoma, although its precise mechanism remains to be clarified. Thus, the present study was undertaken to elucidate the alteration of the microcirculatory structure and the relation to angiogenetic factors in mice infected with H. heilmannii for 3 and 6 months.


METHODS
Immunohistochemical studies have been performed by FITC-dextran intra-aortic infusion or CD31, vascular endothelial growth factor-A, cyclooxygenase 2 antibodies using our recently established model of gastric mucosa-associated lymphoid tissue-type gastric B-cell lymphoma in C57BL/6 mice.


RESULTS
Increased microcirculatory network was recognized surrounding the MALT lymphoma tissues by both the FITC-dextran infusion method and CD31 immunoreactivity. Vascular endothelial growth factor-A immunoreactivity was recognized within the lymphoma tissues as well as in the marginal area, while cyclooxygenase-2 immunoreactivity was localized in the area surrounding the MALT lymphoma tissues.


CONCLUSIONS
Increased microvascular network as well as enhanced VEGF-A immunoreactivity was shown to be related to expansion of the MALT lymphoma formed by Helicobacter heilmannii infection.
Nakamura
Masahiko
M
Center for Clinical Pharmacy and Clinical Sciences, School of Pharmaceutical Sciences, Kitasato University, Minato-ku, Tokyo, Japan. nakamuram@pharm.kitasato-u.ac.jp
Takahashi
Shinichi
S
Matsui
Hidenori
H
Murayama
Somay Yamagata
SY
Aikawa
Chihiro
C
Sekiya
Yukie
Y
Nishikawa
Kaori
K
Matsumoto
Tsukasa
T
Yamada
Haruki
H
Tsuchimoto
Kanji
K
D000818:Animals; D051546:Cyclooxygenase 2 / Q000378:metabolism*; D004195:Disease Models, Animal; D005753:Gastric Mucosa / Q000098:blood supply / Q000201:enzymology / Q000382:microbiology*; D016481:Helicobacter Infections / Q000150:complications / Q000382:microbiology* / Q000503:physiopathology; D018247:Helicobacter heilmannii / Q000472:pathogenicity*; D007150:Immunohistochemistry; D018442:Lymphoma, B-Cell, Marginal Zone / Q000201:enzymology / Q000382:microbiology* / Q000503:physiopathology; D051379:Mice; D008809:Mice, Inbred C3H; D008810:Mice, Inbred C57BL; D008833:Microcirculation; D009389:Neovascularization, Pathologic / Q000201:enzymology / Q000382:microbiology* / Q000503:physiopathology; D019408:Platelet Endothelial Cell Adhesion Molecule-1 / Q000378:metabolism; D013997:Time Factors; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism*
D019408:Platelet Endothelial Cell Adhesion Molecule-1; D042461:Vascular Endothelial Growth Factor A; C467480:vascular endothelial growth factor A, mouse; C077623:Ptgs2 protein, mouse; D051546:Cyclooxygenase 2